EXHIBIT 99.1 Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results – Reports YCANTH™ revenue of $1.9M for fourth quarter and$4.7M for full year 2023 – – Over 200 million lives now covered on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, PA –Feb 29, 2024 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases req ...